Search Bar & Filters
Found 33 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.
Actively Recruiting
Researchers are investigating whether adding intismeran autogene to pembrolizumab after surgery helps prevent cancer from returning in people with non-small cell lung cancer NSCLC whose tumors did not fully respond to treatment before surgery. This randomized phase 3 clinical trial compares pembrolizumab combined with intismeran autogene versus pembrolizumab with placebo in participants with resectable Stage II to IIIB NSCLC. The study focuses on individuals who have not achieved a complete pathological response after neoadjuvant therapy, aiming to improve disease-free survival. Participants receive neoadjuvant treatment consisting of pembrolizumab via intravenous infusion every 3 weeks for up to 4 cycles, combined with background chemotherapy chosen by the investigator. After surgery, the adjuvant treatment phase involves pembrolizumab given intravenously every 6 weeks for up to 7 cycles, plus either intismeran autogene or placebo administered by intramuscular injection every 3 weeks for up to 9 doses. The neoadjuvant phase lasts about 12 weeks, and the adjuvant phase extends up to approximately 42 weeks. During the study, participants will have regular assessments including monitoring for disease recurrence, survival, and quality of life using standardized questionnaires. Researchers will track adverse events and treatment tolerability throughout the trial, with follow-up lasting up to over 8 years to evaluate long-term outcomes. The main measurement is disease-free survival, with additional evaluations of overall survival, distant metastasis-free survival, and lung cancer-specific survival, along with patient-reported quality of life and safety data.
Actively Recruiting
Researchers are studying the safety and effectiveness of pirtobrutinib LOXO-305 compared to ibrutinib in adults with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer and focuses on those with specific genetic markers, like 17p deletions, in one part of the trial. This is a phase 3, open-label study sponsored by Loxo Oncology, Inc. Participants receive either pirtobrutinib or ibrutinib as oral treatments. The study has two parts Part 1 compares pirtobrutinib and ibrutinib in a broad group of participants and may last up to six years, while Part 2 evaluates pirtobrutinib alone in treatment-nafve participants with 17p deletions for up to two years. Treatments are taken by mouth, and participants are randomly assigned to treatment groups. During the study, participants will undergo regular assessments to monitor their response to treatment, including checking for complete or partial remission. Researchers will evaluate progression-free survival, overall survival, duration of response, and tolerability over several years. Safety and effectiveness are closely tracked with scheduled visits and tests until data cutoff or disease progression. Participation can last up to six years depending on the study part.
Actively Recruiting
Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.
Actively Recruiting
Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.
Actively Recruiting
Researchers are evaluating the effect of a 24-week once daily treatment with Treprostinil Palmitil Inhalation Powder TPIP compared with a placebo in adults with Pulmonary Arterial Hypertension PAH. This Phase 3 study aims to assess the impact of TPIP on exercise capacity and safety in participants with various subtypes of PAH, including idiopathic, heritable, drug-induced, and connective tissue disease-associated PAH. Participants will be randomly assigned to receive either TPIP once daily at a starting dose of 80 micrograms, gradually increased up to a maximum tolerated dose of 1280 micrograms, or a matching placebo for 24 weeks. Both treatments are delivered via oral inhalation using a capsule-based dry powder inhaler device. The study is double-blind and includes parallel groups receiving either the active drug or placebo. Throughout the study, participants will undergo assessments including 6-minute walk tests to measure exercise capacity, evaluations of functional class, and biomarker analysis such as N-terminal pro hormone brain natriuretic peptide levels. Researchers will also monitor symptoms using the PAH-SYMPACT questionnaire, track time to clinical worsening events, and assess heart function through imaging measures. Plasma concentrations of the drug will be collected at various time points. The total participation duration is 24 weeks, with safety and efficacy closely monitored during this period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of two fixed-duration drug combinations for adults with previously untreated chronic lymphocytic leukemia CLL. This Phase 3 study compares sonrotoclax plus zanubrutinib against venetoclax plus acalabrutinib to see which therapy better controls the disease. The trial is sponsored by BeOne Medicines and focuses on treatment outcomes in this patient group. Participants receive either sonrotoclax and zanubrutinib or venetoclax and acalabrutinib, both given orally for a set period. After completing the drug regimen, participants enter an observation phase to monitor their health and disease status. The study uses a randomized, parallel design without masking, meaning participants are assigned to one of two treatment groups openly. During the trial, participants undergo regular assessments including imaging to measure disease size, evaluations of bone marrow and organ function, and monitoring for side effects. The primary outcomes include progression-free survival monitored for up to about 70 months and rates of undetectable minimal residual disease measured up to approximately 16 months. Secondary outcomes cover response rates, overall survival, adverse events, and quality of life scores. The total study duration extends to late 2031, allowing long-term follow-up and safety evaluation.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of sonrotoclax combined with zanubrutinib compared to zanubrutinib with placebo in adults who have relapsed or refractory mantle cell lymphoma MCL, a rare and aggressive blood cancer. The study focuses on whether the combination of sonrotoclax and zanubrutinib can better control the disease and improve patient outcomes. Participants will be randomly assigned to one of two groups one receiving sonrotoclax plus zanubrutinib, and the other receiving zanubrutinib plus a placebo. All treatments are taken orally. The placebo is a pill without active medicine. The study design is double-blind, so neither participants nor doctors know which treatment is given during the trial unless medically necessary. The study will last up to approximately 7 years. During this time, participants will visit clinics regularly for treatment, health assessments, blood tests, and tumor imaging. Researchers will measure how long participants live without disease worsening, overall survival, response rates, quality of life, and safety through side effect monitoring. These evaluations will help understand the treatments impact on the disease and patient wellbeing.
1-10 of 33
1